LLY

1,045.02

-0.7%↓

JNJ

203.41

+0.38%↑

ABBV

229.54

-0.76%↓

UNH

311.8

+1.55%↑

AZN

88.66

-0.2%↓

LLY

1,045.02

-0.7%↓

JNJ

203.41

+0.38%↑

ABBV

229.54

-0.76%↓

UNH

311.8

+1.55%↑

AZN

88.66

-0.2%↓

LLY

1,045.02

-0.7%↓

JNJ

203.41

+0.38%↑

ABBV

229.54

-0.76%↓

UNH

311.8

+1.55%↑

AZN

88.66

-0.2%↓

LLY

1,045.02

-0.7%↓

JNJ

203.41

+0.38%↑

ABBV

229.54

-0.76%↓

UNH

311.8

+1.55%↑

AZN

88.66

-0.2%↓

LLY

1,045.02

-0.7%↓

JNJ

203.41

+0.38%↑

ABBV

229.54

-0.76%↓

UNH

311.8

+1.55%↑

AZN

88.66

-0.2%↓

Search

West Pharmaceutical Services Inc

Aperta

SettoreSettore sanitario

254.89 -1.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

252.87

Massimo

259.96

Metriche Chiave

By Trading Economics

Entrata

8.2M

140M

Vendite

38M

804M

P/E

Media del settore

38.933

106.172

EPS

1.96

Rendimento da dividendi

0.32

Margine di Profitto

17.406

Dipendenti

10,600

EBITDA

19M

217M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+34.37% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.32%

2.31%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-889M

19B

Apertura precedente

256.45

Chiusura precedente

254.89

Notizie sul Sentiment di mercato

By Acuity

50%

50%

177 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 nov 2025, 23:36 UTC

Azioni calde

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov 2025, 22:13 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov 2025, 21:55 UTC

I principali Market Mover

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov 2025, 21:43 UTC

Acquisizioni, Fusioni, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov 2025, 23:55 UTC

Discorsi di Mercato

Gold Rises on Possible Investment Demand -- Market Talk

19 nov 2025, 23:54 UTC

Discorsi di Mercato

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov 2025, 23:47 UTC

Utili

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov 2025, 23:46 UTC

Utili

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov 2025, 23:45 UTC

Utili

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov 2025, 23:42 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 nov 2025, 23:41 UTC

Utili

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov 2025, 23:41 UTC

Utili

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov 2025, 23:40 UTC

Utili

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov 2025, 22:55 UTC

Utili

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov 2025, 22:41 UTC

Utili

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov 2025, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov 2025, 22:30 UTC

Utili

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov 2025, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov 2025, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov 2025, 22:08 UTC

Utili

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov 2025, 22:00 UTC

Utili

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov 2025, 21:58 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov 2025, 21:52 UTC

Utili

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

19 nov 2025, 21:49 UTC

Discorsi di Mercato
Utili

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov 2025, 21:38 UTC

Utili

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov 2025, 21:27 UTC

Acquisizioni, Fusioni, Takeovers

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov 2025, 21:24 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Confronto tra pari

Modifica del prezzo

West Pharmaceutical Services Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.37% in crescita

Previsioni per 12 mesi

Media 349.56 USD  34.37%

Alto 375 USD

Basso 311 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per West Pharmaceutical Services Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

10

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

213.26 / 219.27Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

177 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat